This initiative can really be a game changer in bridging the unacceptable inequity in access to cancer care for people in low-income countries. We at the Access to Medicine Foundation have been identifying several specific opportunities for the pharmaceutical industry and their partners to expand access to cancer treatments, and this coalition seeks to solve exactly that.
Jayasree K. Iyer, CEO, Access to Medicine Foundation
At Sanofi, we are delighted to be part of the ATOM Coalition’s initiative and shine a light on cancer care by helping strengthen healthcare systems in LMICs including improving access to essential cancer medicines.
Josep Catlla, Senior Vice President, Head of Corporate Affairs, Sanofi
We are excited to be a partner in this global effort to boost access to essential cancer medicines along with developing processes for ensuring drug quality, safe delivery, and optimal utilisation.
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer, American Society of Clinical Oncology (ASCO)
The patient is at the centre of all that we do as pathologists and medical laboratory professionals. Through this initiative, cancer patients will benefit from access to the best treatments for their specific cancer without fiscal or geographic barriers.
E. Blair Holladay, PhD, MASCP, SCT(ASCP) CM, CEO, American Society of Clinical Pathology (ASCP)
We are committed to working together with the ATOM Coalition and all partners involved to build more sustainable, resilient health systems by prioritising access to diagnosis and treatment for patients living with cancer.
Beth Hamilton, Global Vice President Oncology Market Access & Pricing, AstraZeneca
As part of our mission to drive affordable access to cancer therapies around the world, BeiGene is pleased to join this collaboration alongside other global stakeholders. Collaborations like these are key to creating a more equitable world for cancer care, and we’re excited to get to work.
John V. Oyler, Co-Founder, Chairman and CEO, BeiGene
We are proud to be a partner and look forward to synergizing our oncology access and training programs, sharing best practices, and accelerating equitable access to high-quality cancer care.
Jennifer Dent, President and CEO, BIO Ventures for Global Health (BVGH)
We are proud to partner with the Access to Oncology Medicines (ATOM) Coalition led by the Union for International Cancer Control (UICC), as part of our work to help strengthen health systems capacity, expand access to medical innovation and drive health equity globally.
Amadou Diarra, Senior Vice President, Global Policy, Advocacy and Government Affairs, Bristol Myers Squibb
We welcome the new partnership model established by the ATOM Coalition and we look forward to working with Coalition partners to deliver meaningful impact for people living with cancer in LLMICs, their families and communities.
Mike Boyd, Senior Vice President, Government Affairs and Policy, Gilead Sciences and Chair, Global Health and Access Committee at IFPMA.
IGBA is pleased to join the ATOM Coalition alongside many other global stakeholders. We believe that we can assist this important initiative by providing advice on off-patent medicines policies as well as on functioning frameworks for access to medicines, and support in streamlining regulatory processes.
Vivian Frittelli, Chair, International Generic and Biosimilar medicines Association (IGBA)
We need to push ourselves to share ideas and expertise, inspire new thinking, and co-create new types of solutions for LMICs. We applaud the ATOM Coalition’s efforts to define a multi-stakeholder model that encourages global and local collaborations to positively impact the lives of people living with cancer.
Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
We have witnessed the power of collaborative partnerships to erase the gap in patient outcomes in certain cancers in low- and lower middle-income countries and we believe the launch of the ATOM Coalition is an important milestone on the journey to expand access to cancer medicines for all in need.
Pat Garcia-Gonzalez, CEO, The Max Foundation (Max)
The ATOM Coalition will show that sustainable access for people in low- and lower middle-income countries is eminently feasible and we will no longer have excuses for failing to deliver that access.
Charles Gore, Executive Director, Medicines Patent Pool
Pain and suffering from cancer is felt everywhere on earth; we have to work together in order to advance cancer care for all. NCCN is proud to be part of the ATOM Coalition and everything UICC does to improve cancer outcomes worldwide.
Robert W. Carlson, MD, CEO, National Comprehensive Cancer Network (NCCN)
As part of Novartis' commitment to address the needs of underserved populations and bring our medicines to patients, no matter where they live, we are proud to be the first pharmaceutical company to contribute a targeted therapy to this Coalition, which we hope will provide a new model for the sector to help close the gaps in access to life-changing medicines.
Dr Lutz Hegemann, President, Global Health and Chief Strategy & Growth Officer, Novartis
Too often, whether or not someone is able to receive quality cancer care depends on where they live, their income or the colour of their skin. With our ATOM Coalition partners we will go even further, using the ECHO Model to create more equitable access to cancer screening and treatment for people around the world.
Dr Sanjeev Arora, Founder and Director, Project ECHO
Improving global access to quality cancer care is a core commitment at Roche. We recognise that a challenge of this scale and scope cannot be overcome alone. This is why we have been early supporters of the ATOM Coalition, working closely with our coalition partners to find the best ways to combine our expertise and strengths in diagnostics and pharmaceuticals to make a real difference for patients.
Teresa Graham, Head of Global Product Strategy, Roche Pharma
The Defeat-NCD Partnership is committed to practically collaborating with the ATOM Coalition by making its Essential NCD Supplies Facility available, to ATOM Coalition members, their partner institutions, and programme countries, as the practical pooled procurement mechanism for countries and institutions to benefit from quality-assured, and fairer-priced cancer supplies.
Mukul Bhola, CEO, The Defeat-NCD Partnership
Too many people have their lives cut short because they cannot access quality cancer medicines as part of comprehensive care. WHO is pleased to work with UICC and partners across sectors in the ATOM Coalition to change this reality towards health for all.
Bente Mikkelsen, Director NCD Department, World Health Organization